Autophagy Activator

SMER18 is a small molecule enhancer of rapamycin which act as a mTOR-independent autophagy inducer.

LYN-1604 hydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC).

6-CEPN is a RAS inhibitor. 6-CEPN can inhibit RAS activation by binding to Icmt binding sites. 6-CEPN has anticancer activity. 6-CEPN can block cancer cells in the G1 phase. 6-CEPN can induce autophagy and necrosis of Cancer cells (Icmt: isovalerylcysteine carboxymethyltransferase).

(Rac)-AZD 6482 ((Rac)-KIN-193) is the racemate of AZD 6482. AZD 6482 is a potent and selective p110β inhibitor with an IC₅₀ of 0.69 nM.

YLRPEGDW is an orally active sleep-promoting peptide. YLRPEGDW upregulates Autophagy-related genes, increase Autophagy activity. YLRPEGDW could improve Caffeine-induced sleep reduction.

Sodium propionate-d₃ is the deuterium labeled Propionate sodium (HY-B1773A). Sodium propionate is an orally active short-chain fatty acid. Sodium propionate can be produced by intestinal bacteria from the metabolism of dietary fiber. Sodium propionate increases PPAR-γ, inhibits NF-κB activation, and reduces COX-2 expression and NO production. Sodium propionate also induces Apoptosis and Autophagy. Sodium propionate reduces HSV-1-induced keratitis. Sodium propionate has anticancer effects against glioblastoma. Sodium propionate exhibits neuroprotective, antioxidant, and anti-inflammatory activities. Sodium propionate can be used in the research of spinal cord injury and Alzheimer's disease.

Pravastatin-d₃ (sodium) is the deuterium labeled Pravastatin sodium salt. Pravastatin (CS-514) sodium salt is a competitive HMG-CoA reductase inhibitor against sterol synthesis with IC₅₀ of 5.6 μM.

Sodium propionate-d₅ is the deuterium labeled Propionate sodium (HY-B1773A). Sodium propionate is an orally active short-chain fatty acid. Sodium propionate can be produced by intestinal bacteria from the metabolism of dietary fiber. Sodium propionate increases PPAR-γ, inhibits NF-κB activation, and reduces COX-2 expression and NO production. Sodium propionate also induces Apoptosis and Autophagy. Sodium propionate reduces HSV-1-induced keratitis. Sodium propionate has anticancer effects against glioblastoma. Sodium propionate exhibits neuroprotective, antioxidant, and anti-inflammatory activities. Sodium propionate can be used in the research of spinal cord injury and Alzheimer's disease.

Didrovaltrate (Didrovaltratum) is an L-type calcium channel blocker, ROS scavenger, autophagy enhancer, and lipid accumulation inhibitor. Didrovaltrate blocks L-type calcium currents in a concentration-dependent manner, shifts the current-voltage curve upward, modulates steady-state inactivation kinetics, and inhibits the nuclear translocation of glucocorticoid receptors. Didrovaltrate reduces ROS levels, downregulates the expression of muscle atrophy-related genes, enhances autophagy via lipophagy, and decreases Oleic acid-induced lipid accumulation. Didrovaltrate exhibits cytotoxic activity against cancer cells. Didrovaltrate can be used in research related to skeletal muscle atrophy, non-alcoholic fatty liver disease, breast cancer, lung cancer, gastric cancer, and prostate cancer.

Pravastatin (CS-514) is a competitive HMG-CoA reductase inhibitor against sterol synthesis with IC₅₀ of 5.6 μM.

Pravastatin-d₉ sodium is deuterated labeled Pravastatin (HY-B0165). Pravastatin (CS-514) is a competitive HMG-CoA reductase inhibitor against sterol synthesis with IC₅₀ of 5.6 μM.

Phytic acid (Inositol hexaphosphate hexalithium) hexalithium is an orally active compound. Phytic acid hexalithium can be derived from the seeds of legumes. Phytic acid is a [PO4]³- storage depot and precursor for other inositol phosphates and pyrophosphates. Phytic acid hexalithium attenuates Aβ oligomers and upregulates Autophagy protein. Phytic acid hexalithium can be used in cardiovascular disease, metabolic disease, nervous system disease and cancer research.

SHP2 protein degrader-3 is a SHP2 AUTAC degrader. SHP2 protein degrader-3 shows dose-dependent SHP2 degradation ability (DC₅₀ = 3.22 μM) and anti-tumor activity (IC₅₀ = 5.59 μM) in HeLa cells. SHP2 protein degrader-3 induces degradation through the LC3-mediated autophagy pathway, which can be inhibited by lysosome inhibitors. SHP2 protein degrader-3 induces apoptosis in various cancer cells (HeLa cells, HepG2 cells, LoVo cells, Huh-7 cells) (SHP2 Ligand : (HY-100388); LC3 Ligand: (HY-10542); Linker : (HY-128834)).

2-Methylbiphenyl-oxadiazole-NH-Ph-CHO is a PD-L1 ligand. 2-Methylbiphenyl-oxadiazole-NH-Ph-CHO serves as the PD-L1 ligand of AUTAC PDL1 degrader-2 (HY-169363). 2-Methylbiphenyl-oxadiazole-NH-Ph-CHO activates the autophagy-lysosome system and upregulates autophagy-lysosome-related genes. 2-Methylbiphenyl-oxadiazole-NH-Ph-CHO is applicable for cancer research.

HDAC6-IN-79 is a HDAC6 inhibitor with an IC₅₀ of 98.40 nM, and it also exhibits inhibitory activity against other HDAC subtypes (HDAC1: 639.0 nM, HDAC2: 798.9 nM, HDAC8: 865.7 nM, HDAC4: 1187 nM). HDAC6-IN-79 induces acetylation of α-tubulin and histone H3, reduces the viability of cancer cells, activates the autophagy pathway and induces apoptosis. HDAC6-IN-79 can be used for research related to urothelial carcinoma (bladder cancer).

Ambrosin is an orally active NF-κβ and BACE1 inhibitor. Ambrosin reduces pro-inflammatory and nitrosative mediators, increases PPARγ levels, inhibits apoptosis (Apoptosis), enhances autophagy (Autophagy), and ameliorates oxidative stress. Ambrosin reduces Amyloid plaque deposition. Ambrosin improves lipopolysaccharide-induced memory impairment and colonic histopathological changes. Ambrosin can be used in research related to Alzheimer's disease and colitis.

BRD5631 is an autophagy enhancer, enhances autophagy through an mTOR-independent pathway. BRD5631 affects several cellular disease phenotypes previously linked to autophagy, including protein aggregation, cell survival, bacterial replication, and inflammatory cytokine production.

sGC stimulator 1 is a carbonyl sulfide (COS)/H₂S-donor hybrid soluble guanylyl cyclase (sGC) stimulator (EC₅₀ = 496 nM). sGC stimulator 1 exhibits a well-characterized H₂S-releasing property. sGC stimulator 1 reduces fibrosis in TGF-β1-treated cardiac fibroblasts by increasing cGMP and H₂S levels. sGC stimulator 1 can exert anti-fibrotic effects by activating sGC and increasing H₂S. sGC stimulator 1 can be used for the study of heart failure (HF).

501A054 is an autophagy activator. 501A054 induces autophagy-dependent cell death via autophagy activation. 501A054 can be used in studies on autophagy regulation such as cervical cancer.

Autophagy-lysosome activator-1 (Compound F1) is a Autophagy-lysosome activator. Autophagy-lysosome activator-1 effectively induces PD-L1 or VISTA degradation in tumor cells.